Integra LifeSciences Announces $450 Million Senior Secured Notes

On 9 October 2026, Integra LifeSciences Holdings Corporation (NASDAQ:IART) disclosed the pricing of a new debt instrument that will shape the company’s capital structure for the coming decade. The issuance consists of $450 million in senior secured notes, each bearing a 9.50 % coupon and maturing in 2033.

Key Features of the Notes

  • Principal amount: $450 million aggregate
  • Coupon rate: 9.50 % per annum
  • Maturity: 2033
  • Security: General senior secured obligations, guaranteed by wholly‑owned domestic subsidiaries that back Integra’s senior secured credit facilities
  • Purpose: Part of a broader refinancing strategy that includes new credit facility transactions intended to replace existing debt and cover associated fees and expenses

The notes were priced at a closing date expected around 19 October 2026. By combining the proceeds from the new notes with the drawdown of newly authorized credit facilities, Integra aims to streamline its debt profile, reduce overall borrowing costs, and provide a stable source of capital for ongoing operations in orthopedic, neurosurgical, and reconstructive surgery markets.

Strategic Context

Integra LifeSciences operates as a holding company that supplies a range of medical devices and implants for foot, ankle, hand, wrist, and wound repair. With a market capitalization of approximately $1.05 billion and a 52‑week high of $20.49 (as of 27 July 2026), the company’s financial flexibility is essential for sustaining its product development pipeline and maintaining service quality across the United States.

The 9.50 % senior secured notes, while carrying a relatively high coupon compared to the current interest‑rate environment, offer the advantage of secured priority in the event of default. This feature is particularly valuable for a company whose cash flows are closely tied to the cyclical nature of the health‑care equipment sector.

Implications for Investors

  • Yield attractiveness: The 9.50 % coupon provides a robust return for fixed‑income investors seeking yield in a low‑interest‑rate backdrop.
  • Credit risk profile: The senior secured status, coupled with guarantees from wholly‑owned subsidiaries, mitigates default risk relative to unsecured debt.
  • Market impact: The issuance is expected to be priced in the current market, reflecting investor appetite for high‑yield, secured instruments in the health‑care equipment sector.

Overall, the successful pricing of the senior secured notes positions Integra LifeSciences to strengthen its balance sheet, support continued investment in product innovation, and maintain its competitive standing within the health‑care equipment and supplies industry.